ScholarLens Back to search
2001•Value in HealthOpen access

PDG12: CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS

Boom G van den, MA Koopmanschap, J Caro, Jens Grueger

Open full text 3 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Metformin, Nateglinide, Medicine, Diabetes mellitus, Type 2 diabetes, Internal medicine, Oncology, Pharmacology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
PDG12: CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS — Research Paper | ScholarLens